NYMC Faculty Publications
Dosing of Radioactive Iodine in End-stage Renal Disease Patient with Thyroid Cancer
DOI
10.1530/EDM-17-0111
Journal Title
Endocrinology, Diabetes & Metabolism Case Reports
First Page
17-0111
Document Type
Article
Publication Date
11-1-2017
Department
Radiology
Abstract
We describe detailed administration of thyroidal and extrathyroidal doses of radioiodine to a patient with end-stage renal disease on hemodialysis. A thorough description of area under curve measurements in a patient with compromised renal function has rarely been described in the literature. Few publications have described thyroid cancer management of patients on hemodialysis, and we believe our management will aid in patient treatment in the future. Learning points: Scheduling of hemodialysis is important when administering radioactive iodine.Treatment of thyroid cancer with radioiodine in patients with end-stage renal disease requires multidisciplinary approach coordinating dialysis, nuclear medicine and endocrinologists care.Balancing ideal dosage of I(131) and the timing of dialysis to insure maximal thyroidal uptake and minimal extra thyroidal I(131) concentration is necessary.
Recommended Citation
Bhat, M., Mozzor, M., Chugh, S., Buddharaju, V., Schwarcz, M., & Valiquette, G. (2017). Dosing of Radioactive Iodine in End-stage Renal Disease Patient with Thyroid Cancer. Endocrinology, Diabetes & Metabolism Case Reports, 2017, 17-0111. https://doi.org/10.1530/EDM-17-0111
